High-risk thyroid cancer remains a therapeutic challenge. This live, case-based panel discussion will cover the basics of high risk thyroid cancer from presentation and diagnosis to treatment. A comprehensive discussion on standard and advanced therapeutics will be included. The necessity of a multidisciplinary advanced care team for the management of these patients will be emphasized.

 TARGETED AUDIENCE

Specialties - FAMILY MEDICINE, INTERNAL MEDICINE - Endocrinology, Diabetes and Metabolism, INTERNAL MEDICINE - Hematology, INTERVENTIONAL RADIOLOGY AND DIAGNOSTIC RADIOLOGY, NUCLEAR MEDICINE, OBSTETRICS AND GYNECOLOGY, PATHOLOGY - CLINICAL, PATHOLOGY - Clinical Informatics, PATHOLOGY - Cytopathology, PATHOLOGY - Dermatopathology, PATHOLOGY - Hematopathology, PATHOLOGY - Neuropathology, PATHOLOGY - Pathology-Chemical, PATHOLOGY - Pathology-Molecular Genetic, PATHOLOGY-ANATOMIC/PATHOLOGY-CLINICAL, RADIATION ONCOLOGY, RADIOLOGY - Neuroradiology, RADIOLOGY - Nuclear Radiology, SURGERY
Professions - Nurse Practitioners, Physicians, Radiology Technicians

EDUCATIONAL OBJECTIVES

• Assess the approaches for radioactive iodine therapy in aggressive thyroid cancer
• Identify clinical scenarios where external beam radiation may be indicated
• Review surveillance strategies for high-risk patients and indications for intervention
• Recognize the role of systemic therapy in metastatic thyroid cancer

ACCREDITATION

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  
Penn Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.